The court upheld a judgement of no interference-in-fact from the Patent Trial and Appeal Board, leaving the Broad in control of key CRISPR IP.
In exchange, Editas has the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.
The company — which was cofounded by David Liu, Feng Zhang, and Keith Joung — has licensed base editing technology from Harvard and the Broad Institute.
Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.
The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
The wide-ranging discussion with witnesses from Stanford, Johns Hopkins, and Editas Medicine touched on recent advances in research and questions of safety.
In letters, CRISPR companies respond to a Nature Methods report of off-target editing effects, Technology Review reports.
The company intends to use part of the proceeds of the offering to advance programs including one in Leber congenital amaurosis 10.
The firm plans to sell 4 million shares of common stock to support preclinical studies and clinical trials of CRISPR-based human therapies, among other uses.
Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.
Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.
The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.
Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.
In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.